| Status | Study |
| Recruiting |
Study Name: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Condition: Adult Nasal Type Extranodal NK/T-Cell Lymphoma Adult T-Cell Leukemia/Lymphoma Date: 2016-01-08 Interventions: Other: Laboratory Biomarker Analysis |
| Recruiting |
Study Name: Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Condition: Aggressive Non-Hodgkin Lymphoma Anaplastic Large Cell Lymphoma Date: 2013-02-06 Interventions: Dietary Supplement: Cholecalciferol |
| Recruiting |
Study Name: Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides Condition: CD30 Positive Cutaneous T Cell Lymphoma CD30 Positive Transformed Mycosis Fungoides Date: 2012-07-11 Interventions: Genetic: Genetically modified T cells # 1138 |
| Active, not recruiting |
Study Name: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Condition: Primary Cutaneous Anaplastic Large Cell Lymphoma Mycosis Fungoi Date: 2012-03-27 Interventions: Drug: Brentuximab Vedotin Bren |
| Active, not recruiting |
Study Name: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) Condition: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma Lymphoma, Pr Date: 2011-05-10 Interventions: Drug: SGN-35 1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day |
| Completed |
Study Name: Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Condition: Cutaneous T-cell Lymphoma Mycosis Fungoides Sezary Syndrom Date: 2010-05-28 Interventions: Drug: Pralatrexate Injection |
| Withdrawn |
Study Name: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma Condition: Lymphoma, Large-Cell Date: 2006-03-01 Interventions: Drug: MDX-060 |
| Completed |
Study Name: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Condition: Large Cell Lymphoma Date: 2004-12-10 Interventions: Drug: SGN-30 |